{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:44:01Z","timestamp":1793043841394,"version":"4.5.0"},"reference-count":117,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,17]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The advent of Janus kinase inhibitors (JAKis) inaugurated a novel era in the treatment of myelofibrosis (MF), a myeloproliferative neoplasm with heterogeneous clinical manifestations. Four JAKis have been approved for intermediate or high-risk MF, in the United States. Regulatory approval of the first JAK1\/2 inhibitor, ruxolitinib, in 2011, transformed the landscape of MF by markedly controlling splenomegaly and constitutional symptoms, improving patients\u2019 quality of life, and prolonging survival. Fedratinib, the second approved JAKi, is preferred in the second-line setting. Ruxolitinib and fedratinib can cause myelosuppression and are recommended for patients with the myeloproliferative phenotype. The approval of 2 less-myelosuppressive JAKis, pacritinib and momelotinib, provided essential treatment options for patients with severe thrombocytopenia and anemia, respectively. Momelotinib and pacritinib are potent activin A receptor, type 1 inhibitors with consequent significant benefits for patients with anemia. Transfusion independence was achieved with momelotinib in patients who were severely anemic, and the association of transfusion independence with prolonged overall survival was demonstrated. Judicious treatment decisions regarding JAKis can be made with in-depth understanding of the pivotal clinical trials that evaluated JAKis and their therapeutic attributes and should be guided by the dominant clinical manifestations and the type\/degree of cytopenia(s) (myeloproliferative\/cytopenic phenotypes). This article reviews our clinical approach to treatment with JAKis and their sequencing in patients with MF by presenting 3 clinical vignettes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023022415","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T16:56:27Z","timestamp":1727888187000},"page":"1724-1737","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["How I individualize selection of JAK inhibitors for patients with myelofibrosis"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6624-4196","authenticated-orcid":false,"given":"Lucia","family":"Masarova","sequence":"first","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-4960","authenticated-orcid":false,"given":"Helen T.","family":"Chifotides","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2025042815063214400_bib1","first-page":"119","volume-title":"The MD Anderson Manual of Medical Oncology","author":"Bose","year":"2022","edition":"4th ed."},{"issue":"22","key":"2025042815063214400_bib2","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"issue":"20","key":"2025042815063214400_bib3","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.2217\/fon.15.200","article-title":"A\u00a0comprehensive review of pacritinib in myelofibrosis","volume":"11","author":"Verstovsek","year":"2015","journal-title":"Future Oncol"},{"issue":"9","key":"2025042815063214400_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-019-0236-2","article-title":"Myelofibrosis in 2019: moving beyond JAK2 inhibition","volume":"9","author":"Schieber","year":"2019","journal-title":"Blood Cancer J"},{"issue":"13","key":"2025042815063214400_bib5","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.3390\/cancers15133331","article-title":"Association of myelofibrosis phenotypes with clinical manifestations, molecular profiles, and treatments","volume":"15","author":"Chifotides","year":"2023","journal-title":"Cancers"},{"key":"2025042815063214400_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/bs.ircmb.2021.02.008","article-title":"Mutational landscape of blast phase myeloproliferative neoplasms (BP-MPN) and antecedent MPN","volume":"366","author":"Pasca","year":"2022","journal-title":"Int Rev Cell Mol Biol"},{"issue":"1","key":"2025042815063214400_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2025042815063214400_bib8","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","article-title":"Fedratinib in myelofibrosis","volume":"4","author":"Mullally","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2025042815063214400_bib9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"issue":"9","key":"2025042815063214400_bib10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2025042815063214400_bib11","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.clml.2023.06.004","article-title":"Cross-study comparisons of JAK2 inhibitors in myelofibrosis: risks and recommendations","volume":"23","author":"Mascarenhas","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"2025042815063214400_bib12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2025042815063214400_bib13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"issue":"5","key":"2025042815063214400_bib14","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1097\/HS9.0000000000000553","article-title":"Patient-reported effects of fedratinib, an oral, selective inhibitor of Janus Kinase 2, on myelofibrosis-related symptoms and health-related quality of life in the randomized, placebo-controlled, phase III JAKARTA trial","volume":"5","author":"Mesa","year":"2021","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2025042815063214400_bib15","doi-asserted-by":"crossref","first-page":"S356","DOI":"10.1016\/S2152-2650(21)01822-X","article-title":"MPN-164: overall survival (OS) and progression-free survival (PFS) in patients treated with fedratinib as first-line myelofibrosis therapy and after prior ruxolitinib (RUX): results from the JAKARTA and JAKARTA2 trials","volume":"21","author":"Harrison","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2025042815063214400_bib16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/bjh.18207","article-title":"Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts","volume":"198","author":"Harrison","year":"2022","journal-title":"Br J Haematol"},{"issue":"7","key":"2025042815063214400_bib17","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"issue":"6","key":"2025042815063214400_bib18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure","volume":"95","author":"Harrison","year":"2020","journal-title":"Am J Hematol"},{"issue":"5","key":"2025042815063214400_bib19","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1097\/HS9.0000000000000562","article-title":"Fedratinib improves myelofibrosis-related symptoms and health-related quality of life in patients with myelofibrosis previously treated with ruxolitinib: patient-reported outcomes from the phase II JAKARTA2 trial","volume":"5","author":"Harrison","year":"2021","journal-title":"Hemasphere"},{"issue":"9","key":"2025042815063214400_bib20","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1080\/10428194.2024.2346733","article-title":"Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of the FREEDOM trial","volume":"65","author":"Gupta","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2025042815063214400_bib21","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1016\/S2352-3026(24)00212-6","article-title":"Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"11","author":"Harrison","year":"2024","journal-title":"Lancet Haematol"},{"issue":"8","key":"2025042815063214400_bib22","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/17474086.2022.2112565","article-title":"Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia","volume":"15","author":"Mascarenhas","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"19","key":"2025042815063214400_bib23","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/bloodadvances.2023010151","article-title":"Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis","volume":"7","author":"Oh","year":"2023","journal-title":"Blood Adv"},{"issue":"16","key":"2025042815063214400_bib24","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1182\/bloodadvances.2022007524","article-title":"The Odyssey of pacritinib in myelofibrosis","volume":"6","author":"Venugopal","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2025042815063214400_bib25","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"issue":"7","key":"2025042815063214400_bib26","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2021.279415","article-title":"Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia","volume":"107","author":"Verstovsek","year":"2022","journal-title":"Haematologica"},{"issue":"11","key":"2025042815063214400_bib27","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.clml.2024.06.012","article-title":"Consistency of spleen and symptom reduction regardless of cytopenia in patients with myelofibrosis treated with pacritinib","volume":"24","author":"Gagelmann","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2025042815063214400_bib28","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"issue":"suppl 1","key":"2025042815063214400_bib29","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1182\/blood-2021-146675","article-title":"A\u00a0retrospective head-to-head comparison between pacritinib and ruxolitinib in patients with myelofibrosis and moderate to severe thrombocytopenia [abstract]","volume":"138","author":"Mascarenhas","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2025042815063214400_bib30","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/ejh.14321","article-title":"Pacritinib response is associated with overall survival in myelofibrosis: PERSIST-2 landmark analysis of survival","volume":"114","author":"Ajufo","year":"2025","journal-title":"Eur J Haematol"},{"issue":"suppl 1","key":"2025042815063214400_bib31","doi-asserted-by":"crossref","first-page":"9592","DOI":"10.1182\/blood-2022-163456","article-title":"PACIFICA: a randomized, controlled phase 3 study of pacritinib versus physician\u2019s choice in patients with primary or secondary myelofibrosis and severe thrombocytopenia [abstract]","volume":"140","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"issue":"22","key":"2025042815063214400_bib32","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1182\/bloodadvances.2020003314","article-title":"Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis","volume":"4","author":"Gerds","year":"2020","journal-title":"Blood Adv"},{"issue":"13","key":"2025042815063214400_bib33","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2025042815063214400_bib34","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1038\/s41375-022-01637-7","article-title":"Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis","volume":"36","author":"Mesa","year":"2022","journal-title":"Leukemia"},{"issue":"14","key":"2025042815063214400_bib35","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/bloodadvances.2022009311","article-title":"Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials","volume":"7","author":"Verstovsek","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"2025042815063214400_bib36","doi-asserted-by":"crossref","first-page":"e963","DOI":"10.1097\/HS9.0000000000000963","article-title":"Momelotinib in myelofibrosis patients with thrombocytopenia: post hoc analysis from three randomized phase 3 trials","volume":"7","author":"Kiladjian","year":"2023","journal-title":"Hemasphere"},{"issue":"34","key":"2025042815063214400_bib37","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus Kinase inhibitor-na\u00efve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2025042815063214400_bib38","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/10428194.2024.2328800","article-title":"Momelotinib vs ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial","volume":"65","author":"Gupta","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"2025042815063214400_bib39","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2023-177784","article-title":"Time without transfusion reliance or anemia worsening: a novel method for integrating transfusion dependence, anemia, and survival with myelofibrosis therapies based on the phase 3 SIMPLIFY-1 and SIMPLIFY-2 Trials [abstract]","volume":"142","author":"Mesa","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2025042815063214400_bib40","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"issue":"9","key":"2025042815063214400_bib41","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1007\/s12325-024-02928-4","article-title":"Momelotinib versus continued ruxolitinib or best available therapy in JAK inhibitor-experienced patients with myelofibrosis and anemia: subgroup analysis of SIMPLIFY-2","volume":"41","author":"Harrison","year":"2024","journal-title":"Adv Ther"},{"issue":"suppl 1","key":"2025042815063214400_bib42","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1182\/blood-2023-178772","article-title":"Red blood cell transfusion independence status is an independent predictor of survival: a post-hoc time-dependent analysis of the phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials [abstract]","volume":"142","author":"Gupta","year":"2023","journal-title":"Blood"},{"issue":"10373","key":"2025042815063214400_bib43","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"2025042815063214400_bib44","doi-asserted-by":"crossref","first-page":"e735","DOI":"10.1016\/S2352-3026(23)00174-6","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study","volume":"10","author":"Gerds","year":"2023","journal-title":"Lancet Haematol"},{"issue":"11","key":"2025042815063214400_bib45","doi-asserted-by":"crossref","first-page":"e966","DOI":"10.1097\/HS9.0000000000000966","article-title":"Patient-reported outcomes and quality of life in anemic and symptomatic patients with myelofibrosis: results from the MOMENTUM study","volume":"7","author":"Mesa","year":"2023","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2025042815063214400_bib46","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1182\/blood-2023-177774","article-title":"Longitudinal assessment of transfusion intensity in patients with JAK inhibitor-naive or -experienced myelofibrosis treated with momelotinib in the phase 3 SIMPLIFY-1 and MOMENTUM trials [abstract]","volume":"142","author":"Mesa","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025042815063214400_bib47","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1182\/blood-2022-162877","article-title":"Transfusion independence response as a potential surrogate for overall survival in JAKi-experienced patients with myelofibrosis from MOMENTUM [abstract]","volume":"140","author":"Verstovsek","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025042815063214400_bib48","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00277-021-04682-x","article-title":"Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval","volume":"101","author":"Verstovsek","year":"2022","journal-title":"Ann Hematol"},{"issue":"18","key":"2025042815063214400_bib49","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1002\/cncr.34851","article-title":"The role of therapy in the outcome of patients with myelofibrosis","volume":"129","author":"Masarova","year":"2023","journal-title":"Cancer"},{"issue":"8","key":"2025042815063214400_bib50","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/cncr.34103","article-title":"Improved survival of patients with myelofibrosis in the last decade: single-center experience","volume":"128","author":"Masarova","year":"2022","journal-title":"Cancer"},{"issue":"6","key":"2025042815063214400_bib51","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/10428194.2023.2196593","article-title":"Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy","volume":"64","author":"Pemmaraju","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2025042815063214400_bib52","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1182\/bloodadvances.2021006006","article-title":"Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study","volume":"6","author":"Guglielmelli","year":"2022","journal-title":"Blood Adv"},{"issue":"8","key":"2025042815063214400_bib53","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/14656566.2023.2203318","article-title":"Cytopenic myelofibrosis: prevalence, relevance, and treatment","volume":"24","author":"Vachhani","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"2025042815063214400_bib54","doi-asserted-by":"crossref","first-page":"103862","DOI":"10.1016\/j.critrevonc.2022.103862","article-title":"Anemia in myelofibrosis: current and emerging treatment options","volume":"180","author":"Passamonti","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2025042815063214400_bib55","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/HS9.0000000000000001","article-title":"Myelofibrosis-related anemia: current and emerging therapeutic strategies","volume":"1","author":"Naymagon","year":"2017","journal-title":"Hemasphere"},{"issue":"3","key":"2025042815063214400_bib56","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/ejh.13005","article-title":"Significance of thrombocytopenia in patients with primary and postessential thrombocythemia\/polycythemia vera myelofibrosis","volume":"100","author":"Masarova","year":"2018","journal-title":"Eur J Haematol"},{"key":"2025042815063214400_bib57","doi-asserted-by":"crossref","first-page":"106338","DOI":"10.1016\/j.leukres.2020.106338","article-title":"Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported","volume":"91","author":"Masarova","year":"2020","journal-title":"Leuk Res"},{"issue":"1","key":"2025042815063214400_bib58","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the Mayo Clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"16","key":"2025042815063214400_bib59","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.2022017423","article-title":"Myelofibrosis","volume":"141","author":"Passamonti","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2025042815063214400_bib60","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.6004\/jnccn.2020.7557","article-title":"A\u00a0practical guide for using myelofibrosis prognostic models in the clinic","volume":"18","author":"How","year":"2020","journal-title":"J.\u00a0Natl. Camp. Netw"},{"key":"2025042815063214400_bib61","doi-asserted-by":"crossref","first-page":"20406207221084487","DOI":"10.1177\/20406207221084487","article-title":"A\u00a0retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study","volume":"13","author":"Mead","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"suppl 1","key":"2025042815063214400_bib62","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2020-135872","article-title":"Robust overall survival and sustained efficacy outcomes during long term exposure to momelotinib in JAK inhibitor na\u00efve and previously JAK inhibitor treated intermediate\/high-risk myelofibrosis patients [abstract]","volume":"136","author":"Verstovsek","year":"2020","journal-title":"Blood"},{"issue":"S3","key":"2025042815063214400_bib63","doi-asserted-by":"crossref","first-page":"PB2185","DOI":"10.1097\/01.HS9.0000975492.85817.f0","article-title":"Effect of new or worsening anemia on clinical outcomes in patients with myelofibrosis (MF) treated with ruxolitinib (RUX): a post-hoc analysis of COMFORT-I and -II trials","volume":"7","author":"Al-Ali","year":"2023","journal-title":"Hemasphere"},{"issue":"2","key":"2025042815063214400_bib64","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-022-01767-y","article-title":"Biological drivers of clinical phenotype in myelofibrosis","volume":"37","author":"Mascarenhas","year":"2023","journal-title":"Leukemia"},{"issue":"33","key":"2025042815063214400_bib65","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"2025042815063214400_bib66","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae).Myeloproliferative Neoplasms (Version 1.2024). National Comprehensive Cancer Network; 2024. Accessed 31 January 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1477."},{"issue":"5","key":"2025042815063214400_bib67","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.16462","article-title":"Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts","volume":"189","author":"Al-Ali","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"2025042815063214400_bib68","doi-asserted-by":"crossref","first-page":"8166","DOI":"10.1002\/cam4.5618","article-title":"Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: an Italian MYNERVA Project","volume":"12","author":"Coltro","year":"2023","journal-title":"Cancer Med"},{"key":"2025042815063214400_bib69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/OTT.S53348","article-title":"Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes","volume":"7","author":"Verstovsek","year":"2013","journal-title":"OncoTargets Ther"},{"issue":"1","key":"2025042815063214400_bib70","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1756-8722-6-79","article-title":"Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing","volume":"6","author":"Mesa","year":"2013","journal-title":"J\u00a0Hematol Oncol"},{"issue":"45","key":"2025042815063214400_bib71","doi-asserted-by":"crossref","first-page":"79073","DOI":"10.18632\/oncotarget.18674","article-title":"Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis","volume":"8","author":"Palandri","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"2025042815063214400_bib72","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","article-title":"A\u00a0prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis","volume":"6","author":"Maffioli","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2025042815063214400_bib73","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.3324\/haematol.2016.151449","article-title":"The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies","volume":"101","author":"Gupta","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"2025042815063214400_bib74","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.3109\/10428194.2016.1146950","article-title":"Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis","volume":"57","author":"Al-Ali","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2025042815063214400_bib75","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/cncr.34722","article-title":"Ruxolitinib in cytopenic myelofibrosis: response, toxicity, drug discontinuation, and outcome","volume":"129","author":"Palandri","year":"2023","journal-title":"Cancer"},{"issue":"3","key":"2025042815063214400_bib76","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann Hematol"},{"issue":"1","key":"2025042815063214400_bib77","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-023-01471-z","article-title":"Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety","volume":"16","author":"Verstovsek","year":"2023","journal-title":"J\u00a0Hematol Oncol"},{"issue":"3","key":"2025042815063214400_bib78","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: a systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am J Hematol"},{"key":"2025042815063214400_bib79","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib","volume":"9","author":"Elli","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"2025042815063214400_bib80","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"issue":"8","key":"2025042815063214400_bib81","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"2025042815063214400_bib82","doi-asserted-by":"crossref","first-page":"E185","DOI":"10.1002\/ajh.25489","article-title":"Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms","volume":"94","author":"Rumi","year":"2019","journal-title":"Am J Hematol"},{"issue":"21","key":"2025042815063214400_bib83","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/blood-2019-01-897637","article-title":"Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy","volume":"133","author":"Pemmaraju","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2025042815063214400_bib84","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.17192","article-title":"Second primary malignancy in myelofibrosis patients treated with ruxolitinib","volume":"193","author":"Polverelli","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"2025042815063214400_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","article-title":"Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasms-associated myelofibrosis","volume":"35","author":"Talpaz","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"2025042815063214400_bib86","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1124\/dmd.114.058883","article-title":"The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke\u2019s encephalopathy","volume":"42","author":"Zhang","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"2025042815063214400_bib87","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-020-00392-1","article-title":"Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis","volume":"11","author":"Palandri","year":"2021","journal-title":"Blood Cancer J"},{"issue":"suppl","key":"2025042815063214400_bib88","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/01.HS9.0000847036.30498.e9","article-title":"P1042: safety and tolerability results from the phase 3b FREEDOM trial of fedratinib (FEDR), an oral, selective JAK2 inhibitor, in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX)","volume":"6","author":"Gupta","year":"2022","journal-title":"Hemasphere"},{"issue":"2","key":"2025042815063214400_bib89","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.clml.2023.09.008","article-title":"Real-world use of fedratinib for myelofibrosis following prior ruxolitinib failure: patient characteristics, treatment patterns, and clinical outcomes","volume":"24","author":"Mascarenhas","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025042815063214400_bib90","doi-asserted-by":"crossref","first-page":"20406207221118429","DOI":"10.1177\/20406207221118429","article-title":"Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50\u00a0\u00d7 109\/L to &lt;100\u00a0\u00d7 109\/L) at baseline: the final analysis of EXPAND","volume":"13","author":"Guglielmelli","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"12","key":"2025042815063214400_bib91","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/s41375-021-01261-x","article-title":"Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study","volume":"35","author":"Cervantes","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"2025042815063214400_bib92","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","article-title":"Momelotinib: an emerging treatment for myelofibrosis patients with anemia","volume":"15","author":"Chifotides","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"issue":"4","key":"2025042815063214400_bib93","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/leu.2017.330","article-title":"Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis","volume":"32","author":"Pardanani","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2025042815063214400_bib94","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3324\/haematol.2016.148924","article-title":"A\u00a0phase 1\/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis","volume":"102","author":"Gupta","year":"2017","journal-title":"Haematologica"},{"issue":"18","key":"2025042815063214400_bib95","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1182\/bloodadvances.2020002662","article-title":"ACVR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial","volume":"4","author":"Oh","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2025042815063214400_bib96","doi-asserted-by":"crossref","first-page":"10612","DOI":"10.1002\/cam4.5799","article-title":"Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies","volume":"12","author":"Mesa","year":"2023","journal-title":"Cancer Med"},{"issue":"7","key":"2025042815063214400_bib97","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1080\/10428194.2022.2043304","article-title":"Momelotinib reduces transfusion requirements in patients with myelofibrosis","volume":"63","author":"Mesa","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"2025042815063214400_bib98","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1182\/blood-2019-122506","article-title":"Dynamic and time-to-event analyses demonstrate marked reduction in transfusion requirements for Janus kinase inhibitor-naive myelofibrosis patients treated with momelotinib compared head-to-head with ruxolitinib [abstract]","volume":"134","author":"Mesa","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2025042815063214400_bib99","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3324\/haematol.2023.283106","article-title":"Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib","volume":"109","author":"Mesa","year":"2024","journal-title":"Haematologica"},{"issue":"S3","key":"2025042815063214400_bib100","doi-asserted-by":"crossref","first-page":"e1863563","DOI":"10.1097\/01.HS9.0000971124.18635.63","article-title":"P1057: indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis","volume":"7","author":"Masarova","year":"2023","journal-title":"Hemasphere"},{"issue":"16_suppl","key":"2025042815063214400_bib101","doi-asserted-by":"crossref","first-page":"7065","DOI":"10.1200\/JCO.2023.41.16_suppl.7065","article-title":"Indirect treatment comparison (ITC) of momelotinib (MMB) vs fedratinib (FED) safety in patients (pts) with myelofibrosis (MF)","volume":"41","author":"Masarova","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2025042815063214400_bib102","doi-asserted-by":"crossref","first-page":"S326","DOI":"10.1016\/S2152-2650(22)01438-0","article-title":"MPN-141: retrospective comparison of patient outcomes on pacritinib versus ruxolitinib in patients with myelofibrosis and thrombocytopenia","volume":"22","author":"Harrison","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2025042815063214400_bib103","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/jha2.591","article-title":"Risk-adjusted safety analysis of the oral JAK2\/IRAK1 inhibitor pacritinib in patients with myelofibrosis","volume":"3","author":"Pemmaraju","year":"2022","journal-title":"EJHaem"},{"issue":"11","key":"2025042815063214400_bib104","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2217\/fon-2022-1298","article-title":"Defining ruxolitinib failure and transition to next-line therapy for patients with myelofibrosis: a modified Delphi Panel consensus study","volume":"19","author":"Mascarenhas","year":"2023","journal-title":"Future Oncol"},{"issue":"3","key":"2025042815063214400_bib105","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bjh.14601","article-title":"Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia","volume":"181","author":"Hern\u00e1ndez-Boluda","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"2025042815063214400_bib106","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","article-title":"Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group","volume":"11","author":"Kr\u00f6ger","year":"2024","journal-title":"Lancet Haematol"},{"issue":"3","key":"2025042815063214400_bib107","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1\/2 inhibitors","volume":"22","author":"Shanavas","year":"2016","journal-title":"Biol. Blood Marrow Transpl"},{"issue":"12","key":"2025042815063214400_bib108","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41375-021-01276-4","article-title":"Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT","volume":"35","author":"Kr\u00f6ger","year":"2021","journal-title":"Leukemia"},{"issue":"20","key":"2025042815063214400_bib109","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1182\/blood.2023021218","article-title":"How I treat transplant-eligible patients with myelofibrosis","volume":"142","author":"Kr\u00f6ger","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2025042815063214400_bib110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41408-021-00526-z","article-title":"Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis","volume":"11","author":"Sureau","year":"2021","journal-title":"Blood Cancer J"},{"issue":"7","key":"2025042815063214400_bib111","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2023023719","article-title":"Momelotinib for the treatment of myelofibrosis","volume":"144","author":"Bose","year":"2024","journal-title":"Blood"},{"issue":"11","key":"2025042815063214400_bib112","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/cncr.34707","article-title":"Early intervention in myelofibrosis and impact of outcomes: a pooled analysis of the COMFORT-I and COMFORT-II studies","volume":"129","author":"Verstovsek","year":"2023","journal-title":"Cancer"},{"issue":"2","key":"2025042815063214400_bib113","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.clml.2023.09.008","article-title":"Real-world use of fedratinib for myelofibrosis following prior ruxolitinib failure: patient characteristics, treatment patterns, and clinical outcomes","volume":"24","author":"Mascarenhas","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"3","key":"2025042815063214400_bib114","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/jha2.745","article-title":"Incidence of blast phase in myelofibrosis according to anemia severity","volume":"4","author":"Mora","year":"2023","journal-title":"EJHaem"},{"issue":"11","key":"2025042815063214400_bib115","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1200\/JCO.21.02246","article-title":"Disease modification in myelofibrosis: an elusive goal?","volume":"40","author":"Vachhani","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2025042815063214400_bib116","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood.2024024220","article-title":"Identifying disease-modifying potential in myelofibrosis clinical trials","volume":"144","author":"Ross","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2025042815063214400_bib117","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clml.2021.10.002","article-title":"SOHO state of the art updates and next questions: novel therapies in development for myelofibrosis","volume":"22","author":"Chifotides","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/16\/1724\/2369431\/blood_bld-2023-022415-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/16\/1724\/2369431\/blood_bld-2023-022415-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T15:06:53Z","timestamp":1745852813000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/16\/1724\/518022\/How-I-individualize-selection-of-JAK-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":117,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,4,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022415","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]}}}